Yoshiyuki Kobayashi
About
Yoshiyuki Kobayashi is from Tokyo, Tokyo, Japan. Yoshiyuki works in the following industries: "Pharmaceutical Manufacturing". Yoshiyuki is currently Senior Vice President, Research and Development at Cellshoot Therapeutics, Inc, located in Tokyo, Japan. In Yoshiyuki's previous role as a Drug discovery strategy consultant, Part-time lecturer for Graduate school of Yamaguchi University at Freelance, Yoshiyuki worked in Tokyo, Japan until Sep 2023. Prior to joining Freelance, Yoshiyuki was a Chief Scientific Officer at Curreio, Inc and held the position of Chief Scientific Officer at Tokyo, Japan. Prior to that, Yoshiyuki was a Scientific Advisor, Senior Director, Research function at Daiichi Sankyo Co., Ltd., based in Tokyo, Japan from Apr 2020 to Dec 2020. Yoshiyuki started working as Scientific Advisor, Senior Director, Oncology Function at Daiichi Sankyo Co., Ltd. in Tokyo, Japan in Apr 2019. From Jul 2017 to Mar 2019, Yoshiyuki was Head of ADC alliance management at Daiichi Sankyo Pharma Development, based in Basking Ridge, NJ, USA. Prior to that, Yoshiyuki was a CEO & President at Daiichi Sankyo India Pharma Private Limited, based in Haryana, Gurgaon from Apr 2016 to Jun 2017. Yoshiyuki started working as Vice President, Medicinal Chemistry Research Laboratories at Daiichi Sankyo Co., Ltd in Apr 2015.
Come check out Yoshiyuki Kobayashi's email address on finalscout.com, a free professional database with 500 million business professionals and 200 million companies.
Yoshiyuki Kobayashi's current jobs
Yoshiyuki Kobayashi's past jobs
• Responsible for project management of new drug research and development with a specialization in infectious diseases. • Handling projects involving the injectable carbapenem CS-023 and the sialidase inhibitor CS-8958 as an anti-influenza drug. For both projects, performing promotion of out-licensing overseas and clinical development in Japan. • NDA of CS-8958 was filed in Japan, in Jan,2010. • CS-8958 was approved in Japan in September ,2010.
• Underwent training for project management duties for a later assignment in Japan. • Areas of responsibility included autoimmune disorders and infectious diseases.
Performed the following 3 duties in order to strengthen the research and development pipeline: 1. Discovery of business partners for collaborative research and development and their scientific evaluations. - Spearheaded business negotiations with the following venture businesses for collaborative research and development: Trius Therapeutics, Optimer Pharmaceuticals, Vitae Pharmaceuticals, Momenta, Kosan Bioscience, Rib-X Pharmaceuticals, and Enanta. 2.Led operations and management of Sankyo-funded venture fund with Thomas Weisel Partner and established Kearny Venture Fund as the second fund. 3. Collected information and analysis on European and U.S. research trends of the fields of medicinal chemistry and infectious diseases. Packaged information for consumption by the Tokyo research headquarters and proposed strategies.
(Company name changed due to merger with Daiichi Pharmaceutical Co., Ltd.) Performed the following 3 duties in order to strengthen the research and development pipeline: 1. Discovery of business partners for collaborative research and development and their scientific evaluations. Collaboration projects: - Kai Pharmaceuticals: collaborative development of isoform-specific PKC modulator (January 2006, partnership contract closed out). - Exelixis: collaborative research and development of MR antagonist (April 2006, partnership contract closed out). 2. Led operations and management of Sankyo-funded venture fund with Thomas Weisel Partner. 3. Collected information and analysis on European and U.S. research trends of the fields of medicinal chemistry and infectious diseases. Packaged information for consumption by the Tokyo research headquarters and proposed strategies.
Performed the following 3 duties in order to strengthen the research and development pipeline: 1. Discovery of business partners for collaborative research and development and their scientific evaluations. - Spearheaded business negotiations with the following venture businesses for collaborative research and development: Vitae Pharmaceuticals, Momenta, Activbiotics, and Ceptyr
• Spearheaded the advancement of research projects in the cardiovascular field. • Managed 2 projects on nuclear receptor modulators for improving lipid metabolism and drugs. • Was also in charge of management of proton pump antagonist CS-526 which was a drug for gastrointestinal disorders.
• Led drug design and synthesis of anti-infection drugs. • As the group leader, advanced the following programs: Drug discovery program of oral 1b-methylcarbapenem derivatives as drugs for community-acquired respiratory tract infection, drug discovery program of metallo-b-lactamase inhibitor, and drug discovery research of novel iso-leucyl t-RNA synthetase inhibitor for multidrug-resistant Gram positive bacteria. • Was in charge of analytical chemistry for IND application of injectable 1b-methylcarbapenem CS-023.
• As the group leader, advanced the following programs: Drug discovery program of oral 1b-methylcarbapenem derivatives as drugs for community-acquired respiratory tract infection, drug discovery program of metallo-b-lactamase inhibitor. • Led drug discovery research of a OCIF-like low molecular compound for osteoporosis.
• Continued earlier drug discovery research of a sialidase inhibitor as a drug for influenza.
• Was sent to Glycomed for collaborative research with Sankyo. • Conducted drug discovery research of a cell adhesion inhibitor based on carbohydrate chemistry.
• Participated in drug discovery research of a sialidase inhibitor as a drug for influenza.
• Performed discovery research of new carbohydrate-based drugs. Was involved in the following programs: Synthesis and biological evaluation of lipid-A related compounds, total synthesis and biological evaluation of the novel trehalase inhibitor trehazolin and its related compounds, and drug discovery research of a biofilm inhibitor.
• Performed drug discovery research for cardiovascular diseases and diseases of the central nervous system.